www.fdanews.com/articles/197881-pfizer-and-biontech-report-positive-results-from-covid-19-vaccine-trial
![COVID-19 Clinical Trial](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-CLINICAL-TRIAL.gif?t=1585696642&width=430)
Pfizer and BioNTech Report Positive Results from COVID-19 Vaccine Trial
July 2, 2020
Pfizer and BioNTech have announced positive early results from a phase 1 /2 study of their lead COVID-19 vaccine candidate in the U.S.
All 24 volunteers who received either two 10 mcg or 30 mcg doses of the messenger RNA-based vaccine produced neutralizing antibodies up to 2.8 times more than those seen in recovered COVID-19 patients, and no serious adverse events were reported.
The companies expect to begin a phase 2b/3 trial of the vaccine later this month.